ApicHope: Subsidiary's innovative drug APH03621 tablets approved for clinical trials

Zhitong
2025.10.24 08:10

ApicHope announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of its innovative drug APH03621 tablets, and has received the "Notice of Approval for Drug Clinical Trials." Clinical trials will commence shortly. APH03621 is a new oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist developed by the company, intended for the treatment of endometriosis. Currently, there are no approved GnRH oral small molecule antagonists on the market in China. The approval of clinical trials for APH03621 tablets will not have a significant impact on the company's short-term financial condition or operating performance

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer